



A world map is displayed on a grid background, showing the outlines of all major continents in a muted green color. The map is slightly tilted, with the left side appearing lower than the right. The grid consists of thin, light-colored lines forming a perspective view of the globe.


## **Hepatitis Control plan. Where will we make the difference in the next 5 years?**

Margaret Walker, CEO, ELPA

VHPB Meeting

London, 5 - 6 June, 2015

**ELPA:** 35 members from 27 countries




# Our work

## Science-oriented

- Conducting scientific/advisory meetings with pharmaceutical companies
- Distributing and collecting scientific data to and from ELPA members
- Reviewing protocols, working with EMA

## Policy-oriented

- Conducting policy meetings with ELPA members and other stakeholders in the liver field
- Advocating for patient rights on national and European level
- Engaging with relevant institutional and professional stakeholders



# ELPA 10<sup>th</sup> Anniversary: patients matter!



# What are the challenges?



# How to address them?

National Hepatitis Action Plan



Political will



Guidelines for action




Health economic  
assessment



# How does ELPA contribute?



# **Hepatitis B and C: AN ACTION PLAN FOR SAVING LIVES IN EUROPE**





# Support


## Official supporters:



## Acknowledgement by:

WHO, ECDC, US CDC and HBCPPA

# Structure



# Conclusion

- A small minority of the infected patients are diagnosed
- Most EU-28 countries have not implemented any preventative activities
- There is a **need to develop a consistent, evidence-based approach** to address this silent pandemic at the EU level
- The situation in the US provides a learning opportunity to inform action at both European and national level


# **The Burden of Hepatitis C: THE CASE OF FRANCE AND ROMANIA**

# Background

- A project of ELPA (developed by Quantify Research)
- Selected countries
  - France (best performance in hepatitis management in Europe)
  - Romania (highest prevalence; poor management)
- Objectives
  1. To describe the current burden\* of hepatitis C in Europe
  2. To assess the impact of increased treatment

\* *Burden* refers to clinical outcomes (e.g. quality of life and mortality) and economic ones

# The model




# Case scenarios

- **Scenario A**
  - Patients are treated with current standard of care\* and treatment levels are kept constant throughout the model
- **Scenario B**
  - Patients are treated with current standard of care\* but treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels
- **Scenario C**
  - Patients are treated with drugs of increased efficacy and treatment levels are increased between 2014 and 2018 after which treatment levels are returned to current levels

\*Peg-interferon + ribavirin + protease inhibitor in genotype 1 and Peg-interferon + ribavirin in other genotypes in France (average SVR ~57%).  
Peg-interferon and ribavirin in all genotypes in Romania (average SVR ~33%).


# Economic burden of HCV in Romania

## Scenario A



# Economic burden of HCV in France

## Scenario A



## The study demonstrates that:

- The burden of hepatitis C is substantial
- The total health care cost is projected to increase unless action is taken
- Treatment investment is essential to:
  - Economic efficiency
  - Decreased morbidity and mortality

# Conclusion

- **Today's decisions will have an impact on:**
  - Budgets
  - Health outcomes
  - Quality of life

# Bibliography

1. ELPA, 2015. *Hepatitis B and C: An Action Plan for Saving Lives in Europe*. Available at: <http://www.elpa-info.org/elpa-news---reader/items/elpa-launch-event-action-plan-and-burden-of-hepatitis-c.htm>
2. ELPA, 2015. *Burden of Hepatitis C: The Case of France and Romania*. Available at: <http://www.elpa-info.org/elpa-news---reader/items/elpa-launch-event-action-plan-and-burden-of-hepatitis-c.htm>



# Thank you!

